Awarded contract

Biomedical equipment

Details

Value
GBP 793,233
Topic
Pharmaceutical products
Published
12 November 2020

Tender description

VMIC requires the ability to rapidly develop and optimise upstream processes using a state-of-the-art Quality by Design (QBD) approach to ensure robustness as well as rapid development. The ability to execute a Design of Experiments (DoE) approach is integral to the assurance of robustness and furthermore ensures that the processes developed are well away from the edge of failure. VMIC will be a centre of excellence for vaccine development in the UK, and must also have the capability to respond rapidly to pandemic situations, therefore it requires a solution that will allow rapid development of robust processes for clients whilst also allowing a significant reduction in operator-hours and time to create credible processes for anti-pandemic vaccine candidates. VMIC requires the ability to rapidly develop and optimise upstream processes using a state-of-the-art Quality by Design (QBD) approach to ensure robustness as well as rapid development. The ability to execute a Design of Experiments (DoE) approach is integral to the assurance of robustness and furthermore ensures that the processes developed are well away from the edge of failure. VMIC will be a centre of excellence for vaccine development in the UK, and must also have the capability to respond rapidly to pandemic situations, therefore it requires a solution that will allow rapid development of robust processes for clients whilst also allowing a significant reduction in operator-hours and time to create credible processes for anti-pandemic vaccine candidates. The Sartorius Ambr250 HT system, including installation and 1 year comprehensive service, allows the simultaneous operation of multiple bioreactor vessels working under different operating parameters, with each parameter, addition, feed etc. controlled by robotics in response to a pre-defined operational plan. The time saved using such an automated system is significant and allows for the rapid development of processes in a fraction of the time required using a more traditional approach. It also allows for the scale-down validation of existing processing parameters, thus speeding up the robustness testing and subsequent validation of existing process parameters.

Timeline

  1. Completed: Award published12 November 2020
    Current notice
  2. Completed: Award date12 November 2020

About the buyer

Vaccine Manufacturing and Innovation Centre UK Ltd is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

Relevant CPV codes

  • 33600000 · Pharmaceutical products
  • 38434540 · Biomedical equipment

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

Related buyers

Buyers similar to Vaccine Manufacturing and Innovation Centre UK Ltd.

View all buyers

Win more public sector contracts

Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.